Executive Report: The Strategic Value and Operational Constraints of Indefinite Carryover for the California R&D Tax Credit

I. Executive Summary: The Indefinite Carryover Advantage

Indefinite carryover is a statutory provision ensuring that the unused portion of a qualified California Research and Development (R&D) tax credit never expires, offering perpetual utility against future state income or franchise tax liabilities until the credit balance is fully exhausted.1

This crucial provision maximizes the long-term, deferred value of the credit, transforming it into a permanent, bankable tax asset, which is especially beneficial for high-growth, innovative companies that often experience a significant delay between initial R&D investment and achieving substantial taxable profitability.1 The strategic positioning provided by the indefinite carryover rule immediately signals California’s dedication to long-horizon, high-risk innovation, distinguishing its tax policy for technology and life sciences sectors from the constraints imposed by the federal tax regime.3

II. Statutory Foundation and Core Mechanism of the California R&D Credit

The California Research Credit, codified primarily under Revenue and Taxation Code (R&TC) Section 23609, is designed to incentivize businesses to invest in qualified research activities specifically within the state. This credit often mirrors, but does not perfectly conform to, the federal R&D tax credit provisions of Internal Revenue Code (IRC) Section 41.

A. Mechanics of Credit Generation (R&TC Section 23609)

The state R&D credit is calculated under specific provisions of the R&TC, referencing the IRC as of January 1, 2015.4 California requires that both “qualified research” and “basic research” must be physically conducted within California to be eligible for the state credit.4 This strict sourcing rule is fundamental to claiming the state incentive.

There are traditionally two primary calculation methods:

1. The Regular Method: This calculation determines the credit based on 15% of the excess of California qualified research expenses (QREs) for the taxable year over the base period research expenses.5 The base amount calculation has specific rules, including a minimum floor amount equal to 50% of the current year QREs, applicable even to start-up companies.4
2. Basic Research Payments: An additional credit equals 24% of basic research expenses for university-based research for the taxable year.5 These payments are generally made to qualified organizations, such as universities.3

Historically, taxpayers could also elect the Alternative Incremental Research Credit (AIC) method, which used a smaller three-tiered fixed-base percentage and reduced three-tiered credit rates (1.49%, 1.98%, and 2.48%).5

B. Recent Legislative Volatility: Calculation Methodology Updates

The landscape for calculating the California R&D credit underwent a substantial update with the enactment of Senate Bill 711 (SB 711) for tax years beginning on or after January 1, 2025.8 These changes aim to align California’s calculation rules more closely with federal standards, though key differences remain.

The key legislative modifications are centered on the available calculation methods:

• New Method Introduction (ASC): SB 711 introduces the Alternative Simplified Credit (ASC) calculation method to California law.9 This addition provides a third calculation pathway for taxpayers that does not rely on gross receipts, offering potential benefits, particularly for companies that struggle to meet the base period hurdles under the Regular Method.10 It is important to note that the California ASC rate is set at 3% (or 1.3% for taxpayers with no QREs in the preceding three years), which is significantly lower than the corresponding federal ASC rates (14% and 6%, respectively).10
• Method Repeal (AIC): Concurrent with the introduction of the ASC, the Alternative Incremental Credit (AIC), previously allowed in California, is repealed and is no longer available for election starting in tax years beginning after January 1, 2025.9

The existence of the indefinite carryover provision is crucial when reviewing this legislative volatility. Credits generated under the AIC method, which is now sunsetting, or under the newly available ASC method, must be meticulously tracked over decades. The indefinite carryover guarantees that the value of the tax asset, established under the rules of the generation year, remains perpetually preserved, preventing statutory changes in calculation methodology from retroactively diminishing existing tax assets. This mechanism provides essential stability for tax planning despite ongoing state legislative adjustments to credit calculation rules.

III. The Indefinite Carryover Rule: Regulatory Guidance and Application

The indefinite carryover rule is the defining feature that establishes the California R&D tax credit as a premier incentive for long-term investment.

A. Meaning and Legal Authority

The fundamental meaning of indefinite carryover is straightforward: if a business generates a qualified California R&D tax credit but does not have sufficient tax liability in the current year to utilize the full amount, the unused credits may be carried forward indefinitely until the entire credit balance is exhausted.1 This non-expiring characteristic contrasts sharply with typical tax attributes, such as the federal R&D credit (discussed below).3 The indefinite carryover rule applies even if the taxpayer had no income attributable to a particular business interest in the year the credit was generated.4

A critical limitation is that the California R&D credit cannot, under any circumstances, be carried back and applied against a prior year’s tax liability.4

B. FTB Guidance on Mandatory Utilization (FIFO Rule)

The California Franchise Tax Board (FTB), the state revenue office, provides clear regulatory guidance on the utilization order of carryover credits. The FTB strictly mandates that the carryover credit must be applied to the earliest tax year possible.12

This requirement establishes a strict First-In, First-Out (FIFO) protocol for utilization. If a business possesses carryovers generated in different years (e.g., 2010, 2015, and 2020), the 2010 carryover must be fully utilized or applied against the current year’s tax liability before any portion of the 2015 or 2020 carryovers can be used.13

The compliance mechanism for this rule is detailed in FTB Form 3523, Research Credit. Furthermore, when R&D credits are assigned, such as within a combined reporting group, FTB Form 3544 requires detailed tracking of the original taxable year the credit was generated.14 This administrative requirement is essential for ensuring adherence to the FIFO rule and for tracking the proper expiration dates of other credits that do have finite carryover periods (in contrast to the R&D credit).

The non-expiring nature of the credit means that the state of California holds a perpetually growing, deferred tax liability—a tax expenditure that never sunsets.15 The FTB’s insistence on the FIFO rule and detailed generation year tracking serves as a necessary administrative control for managing this open-ended fiscal obligation. Since this permanent reduction in future tax revenue represents a continuous, escalating exposure, administrative measures are vital to maintain accurate financial accounting. While specific data on the total aggregate indefinite carryover liability is not publicly broken out in standard FTB reports 15, the non-expiring characteristic provides justification for the temporary utilization cap (discussed in Section IV), which acts as a legislative mechanism to manage immediate revenue outflow.

C. California vs. Federal Carryover: The Strategic Distinction

The California indefinite carryover rule offers a decisive strategic advantage over its federal counterpart. The U.S. federal R&D tax credit, while also a powerful incentive, is subject to a finite 20-year carryforward period.2 Once the 20-year period concludes, any remaining unused federal R&D credits expire and are permanently lost.2

The indefinite lifespan of the California credit acts as a profound risk mitigant for innovative businesses, especially startups and companies in sectors with notoriously long development and regulatory cycles, such as biotechnology or advanced manufacturing.1 In such industries, profitability and the ability to utilize tax attributes may take well over 20 years to materialize. The California provision guarantees that the substantial investment risk taken in the early, loss-making years will eventually translate into realized tax savings.

It should be noted that the federal Net Operating Loss (NOL) carryforward is now also generally indefinite, though utilization is limited to 80% of taxable income.17 However, the state R&D credit’s indefinite carryover is a separate, permanent statutory feature specifically targeting innovation investment, existing independently of changes to federal or state NOL rules.5

Table 1 provides a concise comparison of the key carryover rules for both jurisdictions.

Table 1: Comparison of R&D Credit Carryover Rules

IV. Utilization Hurdles: The Temporary $5 Million Credit Limitation (2024-2026)

Despite the inherent indefinite lifespan of the R&D credit, California introduced a temporary utilization constraint to manage state budgetary pressures. This limitation significantly affects the liquidity and immediate strategic deployment of large indefinite carryover balances.

A. The Statutory Constraint

For taxable years beginning on or after January 1, 2024, and before January 1, 2027, California law imposes a $5,000,000 limitation on the application of all business credits.4

This is a utilization cap, meaning the total of current year business credits—including the R&D credit and its accumulated indefinite carryovers—applied to reduce the state tax liability, cannot exceed $5 million annually.4 For taxpayers included in a combined report, this limitation is applied at the group level.4

This measure profoundly impacts profitable corporations that routinely generate or carry over credit balances exceeding the $5 million threshold, effectively deferring their planned utilization of the indefinite carryover asset until the cap sunsets at the end of 2026.21

B. Strategic Options for Disallowed Credits

Credits disallowed due to the $5 million annual utilization cap during this three-year period (2024-2026) must be addressed via one of two strategic options, determined by an irrevocable election.4

1. Extended Carryover (Default Option)

If the taxpayer does not make an election for a refundable credit, the disallowed R&D credits automatically remain as carryovers.4 California law specifies that the carryover period for a disallowed credit is “extended by the number of taxable years the credit was not allowed”.4 Because the R&D credit is already indefinite, this provision acts as a legislative safeguard, confirming that the indefinite life of the credit is not compromised or interrupted by the temporary utilization restriction. These credits retain their FIFO requirement and perpetual lifespan.

2. Irrevocable Refundable Credit Election (FTB Form 3870)

Taxpayers may make an irrevocable election to receive an annual refundable credit amount for the credits disallowed due to the utilization cap.4

The payout structure is defined as follows: the taxpayer claims 20% of the total refundable credit amount annually over a five-year refundable period.4 The timing is crucial; the refundable period begins the third taxable year after the taxable year in which the election is made.4 For instance, an election made with the 2024 return would result in the first 20% tranche being claimed as a cash refund in 2027.

To comply, this irrevocable election must be completed using FTB Form 3870, Election for Refundable Credit, and submitted with an original, timely-filed tax return.4

A significant limitation exists for S corporations: they are explicitly prohibited from electing to make credits taken at the entity level refundable.4

The presence of the $5 million cap transforms the management of the indefinite carryover into a complex capital structure decision. Taxpayers must choose between maintaining the full face value of the deferred tax asset for future tax offsets (the default extended carryover) versus accepting a potential time value discount in exchange for an accelerated stream of cash flow (the refundable credit election).

The refundable credit offers a pathway to liquidity despite the utilization bottleneck. However, the multi-year delay and the 20% annual tranche limit mean the business effectively provides a non-interest-bearing loan to the state for two years before receiving cash. Conversely, the indefinite carryover option defers utilization but preserves the dollar-for-dollar tax offset against future liabilities. The choice between these two options is determined by the business’s immediate cash flow needs, its ability to utilize future tax liabilities, and its long-term tax rate projections.

Table 2: Strategic Options for R&D Credits Disallowed by the $5M Cap (2024-2026)

V. Operational Reporting and Utilization Constraints

Beyond the temporary $5 million cap, several structural constraints dictated by the FTB and R&TC govern the annual utilization of the indefinite carryover pool.

A. Order of Application and Coordination

The application sequence of credits is highly regulated. Business credits, which include the R&D tax credit, must be applied against the “net tax” for personal income filers or “tax” for corporate filers before other types of non-business credits are applied.4

Furthermore, the R&D credit’s utilization is constrained by the Tentative Minimum Tax (TMT) rules in California.19 Historically, business credits could only be used to reduce regular income tax above the tentative minimum tax amount.19 While federal changes (like the PATH Act) allowed “eligible small businesses” to utilize the R&D credit against the Alternative Minimum Tax (AMT), California still retains TMT constraints.11 If a taxpayer’s TMT is higher than its regular tax liability, the ability to utilize the R&D credit (and other business credits) may be substantially limited, forcing larger portions of the current year credit into the indefinite carryover pool.19 This means that TMT acts as a secondary, permanent structural limitation on annual utilization, often resulting in an acceleration of the indefinite carryover balance, independent of the temporary $5 million cap.

B. S Corporation Limitations on Utilization

For S corporations, the application and carryover rules introduce a critical exception to the principle of indefinite carryover.5

1. Pass-Through to Shareholders: The full R&D credit amount calculated under R&TC Section 23609 may be passed through to shareholders on a pro-rata basis for use against their Personal Income Tax liability (PITL).4 This passed-through portion maintains its indefinite carryover status at the shareholder level.
2. Entity Tax Offset: S corporations may utilize a maximum of one-third (1/3) of the calculated credit amount against their 1.5% entity-level franchise tax (or 3.5% for financial S corporations).4
3. Non-Carryover Portion: The remaining two-thirds (2/3) of the S-Corp entity-level credit that cannot be used against the entity tax is specifically disregarded and may not be carried over.5 This non-carryover rule represents a significant and crucial compliance point, as it dictates a mandatory, permanent forfeiture of a portion of the generated credit if not utilized immediately at the entity level. This rule highlights that the indefinite carryover feature primarily benefits the shareholder-level credit component.

VI. Case Study: Multi-Year R&D Credit Carryover and Limitation Modeling

This example models a C-Corporation, Innovate Corp, navigating the generation, indefinite carryover, and utilization limitations, specifically addressing the FIFO rule and the temporary $5 million cap.

Scenario Assumptions for Innovate Corp (C-Corp):

• Tax Liability (Pre-Credit): $10,000,000 annually.
• R&D Credit Carryover from 2023: $1,000,000 (Generated in 2023).
• Current R&D Credit Generated: $10,000,000 annually (2024 and 2025).
• Utilization Cap: $5,000,000 (applies 2024 through 2026).4

The following table demonstrates the credit flow, assuming Innovate Corp elects the default Extended Carryover option for disallowed amounts:

Table 3: Multi-Year R&D Credit Carryover Modeling Under $5M Cap

Analysis of Carryover Application:

In 2024, Innovate Corp’s total available credit ($11M) far exceeded the $5M utilization cap. Under the FIFO rule, the $5M utilized was sourced first from the oldest credit vintage: the $1M carryover from 2023 (exhausting that balance), and the remaining $4M was sourced from the 2024 generated credit. The remaining $6M carryover is therefore entirely attributable to the 2024 generation year.

In 2025 and 2026, the utilization continues to be constrained, requiring meticulous tracking of the vintages. This process demonstrates how the temporary cap, while limiting immediate cash savings, inflates the indefinite carryover balance.

Crucially, in 2027, when the $5M cap is lifted, Innovate Corp can utilize the full amount necessary to offset its liability ($10M). The indefinite nature ensures the remaining $6M carryover balance—generated in 2027—continues forward until full utilization, regardless of how many decades it takes to exhaust the total accumulated credit pool.

Refundable Election Analysis (2024 Disallowed Credit):

If Innovate Corp had elected the refundable option for the $6M in disallowed credit in 2024, the outcome would shift from tax offset to cash flow. The disallowed amount (the remaining $6M of the 2024 generated credit) would be the basis for the refundable election. Since $5M was allowed in 2024, the full $6M disallowed portion could be subject to the refundable election.

• The five-year refundable period starts in 2027 (Year 3).
• Innovate Corp would receive $1.2M (20% of $6M) as a cash refund annually in 2027, 2028, 2029, 2030, and 2031.

This analysis shows that the indefinite carryover maintains the full future tax benefit, whereas the refundable election provides immediate cash but delays the start of the refund stream, requiring careful financial modeling to determine the net present value of each path.

VII. Strategic Recommendations and Conclusion

A. Key Strategic Takeaways

1. Indefinite Value Maximized: The non-expiring nature of the California R&D credit elevates it from a mere deduction to a perpetual, bankable deferred tax asset, distinguishing it fundamentally from most federal incentives. This permanent value necessitates its classification as a strategic corporate asset on the balance sheet.
2. Compliance Requires Granularity (FIFO): The FTB’s insistence on the First-In, First-Out (FIFO) rule and the requirement to track the original generation year of the credit mandate meticulous record-keeping. Failure to correctly track carryover vintages jeopardizes future tax utilization and compliance, particularly in the context of corporate reorganizations or assignments (Form FTB 3544).
3. Active Management of the Temporary Cap: The 2024–2026 $5 million utilization cap demands immediate strategic modeling by high-credit taxpayers. Businesses must formally determine the optimal approach: deferring the benefit by allowing the credit to flow into the extended indefinite carryover pool, or accelerating cash flow by making the irrevocable FTB 3870 refundable election. This decision hinges on the current cost of capital versus the expected future value of tax offsets.

B. Conclusion

The Indefinite Carryover provision of the California R&D tax credit (R&TC Section 23609) remains one of the most powerful state tax incentives available to encourage innovation globally. While state budgetary requirements have introduced a utilization cap through 2026, creating temporary liquidity constraints, the underlying statutory guarantee that the credit will never expire ensures that investment in California research activities is protected over the entire business life cycle. For tax and finance leaders, successful navigation requires sophisticated carryover tracking, proactive election strategies, and continuous modeling of the interplay between the perpetual carryover asset and temporary utilization hurdles.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/